Literature DB >> 6145646

Cyclosporine inhibits prolactin induction of ornithine decarboxylase in rat tissues.

D H Russell, D F Larson, S B Cardon, J G Copeland.   

Abstract

Cyclosporine (CyA), formerly cyclosporin A, significantly inhibited the ability of prolactin (PRL) to elevate ornithine decarboxylase (ODC) activity in a variety of rat tissues. Administration of PRL to hypophysectomized rats also resulted in an induction of ODC activity which was inhibited markedly in all tissues studied in the presence of CyA. Transglutaminase ( TGase ) activity was not affected in any significant manner by PRL or CyA in most tissues studied. However, it was elevated in the adrenal by 10(-8) M PRL. Bromocryptine, which selectively antagonizes pituitary PRL release, decreased the kidney ODC basal levels to 30% of vehicle control and serum PRL level to 4.3 +/- 1.4 compared to 28 +/- 10 in controls, suggestive of PRL maintenance of steady-state ODC activity in the kidney. CyA administration did not affect the action of glucagon, a known cyclic AMP-mediated hormone, or 8-bromo-cyclic AMP on kidney ODC activity. The elevation of rat kidney ODC activity by dexamethasone and triiodothyronine (T3), compounds which elevated serum prolactin levels in all cases, was also blocked by administration of CyA. Epidermal growth factor (EGF), which did not induce rat kidney ODC activity by itself, was capable of producing a small increment in ODC activity in the presence of CyA. The marked effect of CyA to selectively block ODC induction by PRL may be due to the ability of CyA to interact with receptor-required phospholipids in membranes and thus to antagonize hormone-receptor interaction.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6145646     DOI: 10.1016/0303-7207(84)90012-1

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  12 in total

1.  Cyclosporine and alpha-difluoromethylornithine exhibit differential effects on colon and pancreatic cancer in vitro.

Authors:  R Saydjari; C M Townsend; S C Barranco; J C Thompson
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

2.  Neonatal administration of prolactin antiserum alters the developmental pattern of T- and B-lymphocytes in the thymus and spleen of BALB/c female mice.

Authors:  D H Russell; K T Mills; F J Talamantes; H A Bern
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

3.  Synergism between long-acting bromocryptine microcapsules and cyclosporine A in the prevention of various autoimmune diseases in rats.

Authors:  M Neidhart
Journal:  Experientia       Date:  1996-09-15

4.  Effect of prolactin on DNA methylation in the liver and kidney of rat.

Authors:  P M Reddy; P R Reddy
Journal:  Mol Cell Biochem       Date:  1990-06-01       Impact factor: 3.396

5.  Does hyperprolactinemia affect hepatic regeneration independent of sex steroids?

Authors:  D Kahn; J S Gavaler; L Makowka; P Chapchap; V Mazzaferro; A Casavilla; M S Smith; P K Eagon; T E Starzl; D H Van Thiel
Journal:  J Lab Clin Med       Date:  1988-11

6.  Rapid activation of protein kinase C in isolated rat liver nuclei by prolactin, a known hepatic mitogen.

Authors:  A R Buckley; P D Crowe; D H Russell
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

7.  Morphometric and ultrastructural analysis of the effect of bromocriptine and cyclosporine on the vasospastic femoral artery of rats.

Authors:  Mehmet Tokmak; Kahan Başocak; Hüseyin Canaz; Gökhan Canaz; Celal İplikçioğlu
Journal:  Int J Clin Exp Med       Date:  2015-10-15

8.  Prolactin-provoked alterations of cytosolic, membrane, and nuclear protein kinase C following partial hepatectomy.

Authors:  A R Buckley; P D Crowe; P A Bauman; L A Neumayer; H E Laird; D H Russell; C W Putnam
Journal:  Dig Dis Sci       Date:  1991-09       Impact factor: 3.199

9.  Bromocriptine and low dose cyclosporine in the treatment of experimental autoimmune uveitis in the rat.

Authors:  A G Palestine; C G Muellenberg-Coulombre; M K Kim; M C Gelato; R B Nussenblatt
Journal:  J Clin Invest       Date:  1987-04       Impact factor: 14.808

Review 10.  Targeting incretin hormones and the ASK-1 pathway as therapeutic options in the treatment of non-alcoholic steatohepatitis.

Authors:  Alexander J Kovalic; Sanjaya K Satapathy; Naga Chalasani
Journal:  Hepatol Int       Date:  2018-03-29       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.